Effectiveness of dry needling compared to placebo needling for easing pain and disability among adults with migraine headache: A Randomized Controlled Trial

Not Applicable

Conditions: Migraine Headache

Registration Number: SLCTR/2024/009

Lead Sponsor: niversity of Peradeniya

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: Not specified

Inclusion Criteria

•Adult patients with migraine headache
* Minimum age 18 and maximum age 50 years
•Diagnosis should be confirmed by a consultant neurologist based on the International Classification
of Headache Disorders (ICHD-3).
•Patients should have at least one active trigger point in their suboccipital and cervical musculature.

Exclusion Criteria

•Patient with a history of neck trauma, cervical radiculopathy
•Patients with previous surgery on the neck or shoulder area
•Patients with abnormal bleeding tendencies, a severely compromised immune system, vascular
disease
•Frail patients,
•Patients with epilepsy
•Patient allergic to metals or latex
•Patients with altered psychological status,
•Patient with prosthetic implants, and implantable electrical devices.
•Patients with a history of physiotherapy intervention in the neck and shoulder region in the previous
six months
•Pregnancy
•Patients with needle phobia
•Patients who are on anticoagulant therapy
•Patients with thrombocytopenia and those with lymphedema in a specific area or limb.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Headache intensity and frequency will be measured by using visual analogue scale and headache diary. <br><br>Headache frequency of the participants will be measured by maintaining a headache diary to record the number of headaches and duration (minutes/hours) per day in a week. Headache frequency is calculated as the weekly average for each subject as a primary outcome measure during the time frame of research conducts. [At the baseline, 1 week after the commencement of intervention, and at the end of 4 weeks]<br>

Secondary Outcome Measures

Name	Time	Method
Migraine-related disability and Quality of Life will be measured by using the Headache Impact Test (HIT) and Headache Disability Inventory questionnaires. <br><br>Migraine-related disability will be measured by using the Migraine Disability Assessment (MIDAS) questionnaire in both treatment [At the baseline, end of the treatment protocol after one week of DN therapy, and 4 weeks after the intervention]<br>